Risk Enhancers, Calcium Scoring, and the Full Picture of Cardiovascular Prevention

The 2026 guideline extends well beyond the PREVENT score to capture the full complexity of individual cardiovascular risk. Certain patient groups warrant a Class I statin indication independent of risk calculator output: those with severe primary hypercholesterolemia (LDL ≥190 mg/dL, signaling likely familial hypercholesterolemia), patients with diabetes aged 40–75 with additional risk factors (LDL target <70 mg/dL), and individuals with stage 3-4 chronic kidney disease or HIV. For these populations, early and intensive treatment is the default.

For patients whose risk remains uncertain after applying the PREVENT score, the guideline formally recognizes several risk-enhancing factors that should prompt more aggressive therapy. These include elevated lipoprotein(a), high-sensitivity C-reactive protein above 2 mg/L, adverse pregnancy outcomes (preeclampsia, gestational diabetes), early menopause before age 45, polycystic ovary syndrome, autoimmune conditions such as lupus or rheumatoid arthritis, and the broader cardio-kidney-metabolic spectrum.

When uncertainty persists even after accounting for risk enhancers, the guideline now designates coronary artery calcium (CAC) scoring as a Class I option for men over 40 and women over 45. A CAC score above 100 or above the 75th percentile for age and sex favors an LDL target below 70 mg/dL; a score above 300 or 1000 supports the more intensive target of below 55 mg/dL. A score of zero, however, should not automatically preclude treatment—calcified plaque is a late-stage finding, and younger adults with elevated LDL, high lipoprotein(a), or strong family history may still benefit from preventive therapy. The guideline's CPR framework—Calculate, Personalize, Reassess—reminds clinicians that risk is not static and should be revisited regularly as patients age and their clinical profiles evolve.